Oric Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 18, 2025
ORIC$9.23+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(127,847) | $(100,697) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 1,107 | 1,032 |
| Stock-based compensation expense | 20,213 | 15,226 |
| Loss on fixed asset disposals | — | 22 |
| Accretion of discount on investments, net | (8,103) | (6,169) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 143 | 1,620 |
| Accounts payable and accrued other liabilities | 1,825 | 3,278 |
| Net cash used in operating activities | (112,662) | (85,688) |
| Cash flows from investing activities: | ||
| Acquisitions of property and equipment | (1,188) | (849) |
| Purchases of investments | (251,920) | (239,244) |
| Maturities of investments | 275,245 | 196,690 |
| Net cash provided by (used in) investing activities | 22,137 | (43,403) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock and pre-funded warrants | 125,000 | 85,000 |
| Issuance costs associated with financings | (168) | (227) |
| Proceeds from issuance of common stock under ESPP | 1,084 | 826 |
| Proceeds from stock option exercises | 631 | 59 |
| Net cash provided by financing activities | 126,547 | 85,658 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 36,022 | (43,433) |
| Cash, cash equivalents and restricted cash at beginning of period | 23,875 | 67,308 |
| Cash, cash equivalents and restricted cash at end of period | $59,897 | $23,875 |
NOTES TO FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.